Council for Innovation Promotion

Fact Check: The Patent Eligibility Restoration Act Would Promote Medical Innovation

Claim: During a January 23 Senate Judiciary Subcommittee on Intellectual Property hearing, Richard Blaylock — on behalf of Invitae Corporation — claimed that “PERA as introduced would stifle innovation and harm patient care in the fields of diagnostic genetic testing and precision medicine.” Correction: The Patent Eligibility Restoration Act (PERA) is an essential reform to […]

Fact Check: The Patent Eligibility Restoration Act Would Promote Medical Innovation Read More »

C4IP Accepting Applications For Prestigious D.C. Summer 2024 Internship

WASHINGTON, D.C. (February 12, 2024) — Today, the Council for Innovation Promotion (C4IP) opened applications for its summer internship program based in Washington, D.C. Interns will have an opportunity to work directly with nationally recognized IP experts, including two past directors of the U.S. Patent and Trademark Office and two former Judges of the United States Court of Appeals for the Federal Circuit.

C4IP Accepting Applications For Prestigious D.C. Summer 2024 Internship Read More »

Celebrating American Innovation: John Kellogg

C4IP is recognizing John Kellogg, whose invention of the first breakfast cereal transformed American nutrition. John Harvey Kellogg was born in Michigan in February 1852. Kellogg learned early on to value healthy living, which ultimately led him to pursue a career in medicine. He studied at the University of Michigan Medical School and later at Bellevue Hospital Medical College, where

Celebrating American Innovation: John Kellogg Read More »

Fact Check: Misusing the Bayh-Dole Act’s March-In Rights is Not an Effective Way to Reduce Drug Prices

Claim: On December 7, the Biden administration proposed a policy framework claiming a newfound authority, under the 43-year-old Bayh-Dole Act, to rescind patent licenses on drugs, energy, climate change, and all other inventions that benefit from federal research funding based on the price of the resulting product. The administration asserts that this framework is an

Fact Check: Misusing the Bayh-Dole Act’s March-In Rights is Not an Effective Way to Reduce Drug Prices Read More »

Scroll to Top